Abstract
The clinical effectiveness of 23-valent pneumococcal vaccine in human immunodeficiency virus (HIV)-infected patients is controversial, because of the low immunological response in these subjects. We studied the clinical response of pneumococcal vaccine and the relative impact of influenza vaccine by administering both pneumococcal and influenza vaccine in a group of 150 HIV patients belonging to all CDC categories. In the group of 90 HIV-infected patients vaccinated against both pneumonia and influenza virus, there was a low incidence of mild influenza (13.3%) and no case of pneumococcal pneumonia. On the contrary, among 60 nonvaccinated HIV patients, 61.6% underwent mild to severe influenza and two developed pneumococcal pneumonia. 23-valent pneumococcal vaccine (PV) seems to be clinically effective in preventing pneumonia in HIV-infected patients, and even more if strengthened by influenza vaccine.
| Original language | English |
|---|---|
| Pages (from-to) | 407-409 |
| Number of pages | 3 |
| Journal | AIDS Research and Human Retroviruses |
| Volume | 21 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 2005 |
Fingerprint
ASJC Scopus subject areas
- Immunology
- Virology
Cite this
Impact of influenza vaccine on response to vaccination with pneumococcal vaccine in HIV patients. / Ranieri, Roberto; Veronelli, A.; Santambrogio, C.; Pontiroli, A. E.
In: AIDS Research and Human Retroviruses, Vol. 21, No. 5, 05.2005, p. 407-409.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of influenza vaccine on response to vaccination with pneumococcal vaccine in HIV patients
AU - Ranieri, Roberto
AU - Veronelli, A.
AU - Santambrogio, C.
AU - Pontiroli, A. E.
PY - 2005/5
Y1 - 2005/5
N2 - The clinical effectiveness of 23-valent pneumococcal vaccine in human immunodeficiency virus (HIV)-infected patients is controversial, because of the low immunological response in these subjects. We studied the clinical response of pneumococcal vaccine and the relative impact of influenza vaccine by administering both pneumococcal and influenza vaccine in a group of 150 HIV patients belonging to all CDC categories. In the group of 90 HIV-infected patients vaccinated against both pneumonia and influenza virus, there was a low incidence of mild influenza (13.3%) and no case of pneumococcal pneumonia. On the contrary, among 60 nonvaccinated HIV patients, 61.6% underwent mild to severe influenza and two developed pneumococcal pneumonia. 23-valent pneumococcal vaccine (PV) seems to be clinically effective in preventing pneumonia in HIV-infected patients, and even more if strengthened by influenza vaccine.
AB - The clinical effectiveness of 23-valent pneumococcal vaccine in human immunodeficiency virus (HIV)-infected patients is controversial, because of the low immunological response in these subjects. We studied the clinical response of pneumococcal vaccine and the relative impact of influenza vaccine by administering both pneumococcal and influenza vaccine in a group of 150 HIV patients belonging to all CDC categories. In the group of 90 HIV-infected patients vaccinated against both pneumonia and influenza virus, there was a low incidence of mild influenza (13.3%) and no case of pneumococcal pneumonia. On the contrary, among 60 nonvaccinated HIV patients, 61.6% underwent mild to severe influenza and two developed pneumococcal pneumonia. 23-valent pneumococcal vaccine (PV) seems to be clinically effective in preventing pneumonia in HIV-infected patients, and even more if strengthened by influenza vaccine.
UR - http://www.scopus.com/inward/record.url?scp=20444368775&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20444368775&partnerID=8YFLogxK
U2 - 10.1089/aid.2005.21.407
DO - 10.1089/aid.2005.21.407
M3 - Article
C2 - 15929703
AN - SCOPUS:20444368775
VL - 21
SP - 407
EP - 409
JO - AIDS Research and Human Retroviruses
JF - AIDS Research and Human Retroviruses
SN - 0889-2229
IS - 5
ER -